A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study).

"Conflict of interest: L.J. is an employee and stockholder of Novartis. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. All other authors have no conflict of interests to declare."

"Funding AGES-RS: The National Institute of Aging contracts N01-AG-12100 and HHSN271201200022C for Vi.G. financed the study. Vi.G. received funding from the National Institute of Aging (1R01AG065596-01A1), and I.H.A received a grant from Althingi (the Icelandic Parliament). T.J. and Va.G. were supported by the Icelandic Centre for Research (grant no. 206692-051) and the University of Iceland Research Fund. The protein measurements in AGES-RS were supported by Novartis Biomedical Research. CHS: This research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and 75N92021D00006 and grants U01HL080295, U01HL130114, and HL144483 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the NIA. J.S.F was supported by National Heart Lung Blood Institute grant R01HL149706. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Conflict of interest: L.J. is an employee and stockholder of Novartis. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. All other authors have no conflict of interests to declare."